Better outcomes for patients with HR+/HER2- breast cancer: spotlight on CDK4/6 inhibitors

Australie

$0

gratuit

RACP

1 heure

Oncology, Screening & Prevention, Women's Health

1 Credits

This course is expired! Browse All Courses
APPRENDRE ENCORE PLUS

Description du cours

This 1-hour interactive online education program is designed to provide medical oncologists with a practical overview of CDK4/6 inhibitors, and their current use in the Australian breast cancer management landscape. The program highlights real-world evidence pertaining to CDK4/6 inhibitors, and features video Q&A with Dr Shom Goel of the Peter MacCallum Cancer Centre to highlight practical applications of established and emerging data.

This program has been endorsed by the Clinical Oncology Society of Australia (COSA), and sponsored by an independent educational grant provided by Pfizer.

Détails du cours

Date d'expiration : 2023-06-08

Métiers: Spécialiste

Faculté

Dr Shom Goel, B Med Sci (Hons), MBBS (Hons), FRACP, PhD
(Melbourne, VIC)

Dr Elgene Lim, MBBS FRACP PhD
(Sydney, NSW)

Dr Otto Metzger, M.D.
(Boston, MA)

Accréditation

This interactive online learning activity is valued at 1 Hour of continuing education with RACP.

Objectif(s) d'apprentissage

On completion of this program, participants will be better able to:

  • Outline efficacy data for CDK4/6 inhibitors as first- and second-line therapy for advanced hormone receptor-positive breast cancer
  • Identifier when is it appropriate to use a CDK4/6 inhibitor as first-line therapy for advanced hormone receptor-positive breast cancer
  • Décrire the adverse effects of the available CDK4/6 inhibitors, how they differ and what the guidelines recommend regarding monitoring and management of toxicity
  • Recognise baseline risk of adverse effects and potential drug-drug interactions
This course is expired! Browse All Courses